Premium
ERG Overexpression and PTEN Status Predict Capsular Penetration in Prostate Carcinoma
Author(s) -
Nagle Raymond B.,
Algotar Amit M.,
Cortez Connie C.,
Smith Katherine,
Jones Carol,
Sathyanarayana Ubaradka G.,
Yun Steven,
Riley Janice,
Nagy Dea,
Dittamore Ryan,
Dalkin Bruce,
Brosh Laura,
Pestano Gary
Publication year - 2013
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.22675
Subject(s) - pten , erg , prostate , tmprss2 , prostate cancer , medicine , immunohistochemistry , cancer research , carcinoma , lesion , oncology , pathology , cancer , pi3k/akt/mtor pathway , biology , apoptosis , ophthalmology , genetics , retinal , disease , covid-19 , infectious disease (medical specialty)
BACKGROUND This study examines the combined effect of two common genetic alterations, ERG and PTEN, in prostate carcinoma progression. METHODS Prostate tissue from 90 patients having unilateral capsular penetrating lesions, and a contra‐lateral organ confined second lesion, were examined by immunohistochemistry for the expression of the TMPRSS2:ERG transformation product ERG and the loss of expression of PTEN, a powerful phosphatase inhibiting the PI3 kinase pathway. Multivariate logistic regression was carried out to analyze the data. RESULTS After adjusting for Gleason score, the odds of having capsular penetration were 5.19 times higher ( P = 0.015) for ERG+/PTEN− group as compared to the wild type (ERG−/PTEN+). CONCLUSIONS This study presents the first evidence that ERG over expression and PTEN deletion is associated with greater risk of capsular penetration. Although further studies are needed, these results have the potential to change clinical assessment for prostate cancer. Prostate 73: 1233–1240, 2013. © 2013 Wiley Periodicals, Inc.